I-Survodutide ne Tirzepatide: Ziyawafanisana Kanjani?

I-Survodutide ne tirzepatide zombili imithi yokujova esaziswa ngayo ukunciphisa umzimba kanye nempilo ye-metabolic. Umehluko omkhulu ukuthi i-tirzepatide inesivumelwane se-FDA futhi iyatholakala kalula, kanti i-survodutide isesikhathini sezivivinyo zezokwelapha futhi ayikatholakali emphakathini. Ziphinde zisebenze ngezindlela ezahlukene zamahomoni, okungaba nencazelo ezinhlosweni ezithile zezempilo.

Uma uzama ukuqonda ukuthi le mithi emibili iyawafanisana kanjani, nansi lokho ucwaningo olukubonisa kuze kube manje.

Lemithi Eyenza Kanjani?

Zombili le mithi ziyi-dual agonists, okusho ukuthi zenza imicwane yamahomoni amabili ngesikhathi esisodwa. Kodwa-ke, izibambambalo zamaresepti ezihlose ngazo zehlukanisiwe, futhi lokho kuguqula indlela ezithinta ngayo umzimba wakho.

I-Tirzepatide ihlose amaresepti e-GLP-1 kanye ne-GIP. I-GLP-1 (glucagon-like peptide-1) yehlisa ukulangazelela ukudla, yehlisa ukushiyeka esiswini, futhi isiza ukulawula ushukela egazini. I-GIP (glucose dependent insulinotropic polypeptide) yandisa ukukhululwa kwe-insulin futhi ingathonya indlela umzimba wakho ophatha ngayo amafutha. Ngokuhlanganisa, lezi zindlela ezimbili zidala imiphumela eqinile kokulawulwa kukashukela egazini kanye nokuncipha komzimba. I-Tirzepatide ithengiswa ngaphansi kwamagama omkhiqizo athi Mounjaro (ku-type 2 diabetes) kanye ne-Zepbound (ukuphathwa kwesisindo).

I-Survodutide ihlose amaresepti e-GLP-1 kanye ne-glucagon. Ibalekela umsebenzi wokunciphisa ukulangazelela ukudla we-GLP-1 ne-tirzepatide, kodwa esikhundleni se-GIP, yenza umzila we-glucagon usebenze. I-Glucagon isiza umzimba wakho ukwandisa ukusetshenziswa kwamandla nokushisa amafutha agciniwe, ikakhulukazi amafutha esibindini. Lokhu kwenza i-survodutide ibe nentshisekelo kakhulu ezinkingeni ezifana ne-MASH (metabolic dysfunction-associated steatohepatitis), uhlobo oluqhubekayo lwesifo samafutha esibindini.

Ngakho-ke i-tirzepatide igxila ekulangazeleleni ukudla kanye nokuthumela isignali kwe-insulin, kanti i-survodutide igxila ekulangazeleleni ukudla kanye nokushiswa kwamandla. Zombili zihola ekunciphisweni komzimba, kodwa ngezindlela ezihlukene kancane.

Idatha Yokuncipha Komzimba Ikhombisa Yini?

Lapha yilapho abantu abaningi bafuna impendulo ecacile. Ngokusekelwe kudatha yezivivinyo zezokwelapha ezitholakalayo, i-tirzepatide okwamanje ikhombisa imiphumela emikhulu yokuncipha komzimba kune-survodutide.

Ucwaningo olukhulu lwango-2022 lwabahlanganisiwe abangu-2,539 lwathola ukuthi i-tirzepatide kumavolumu aphakathi kuka-5 no-15 mg ibanga 15 kuye ku-20.9% yokuncipha komzimba ngemuva kwamasonto angu-72. Ngisho nangamasonto angu-48, abahlanganisiwe babone cishe u-14% kuya ku-19% wokuncipha komzimba. Abanye abasebenzisi bangempela babike ukulahlekelwa u-20% wesisindo somzimba wabo.

Isivivinyo sezidakamizwa zokukhuluphala komzimba se-survodutide esohlwini lwesigaba sesibili sabahlanganisiwe abangu-387 sabonisa u-6.2% kuye ku-14.9% wokuncipha komzimba kumavolumu aphezulu ngemuva kwamasonto angu-46. Umphumela ophakeme kakhulu wokuncipha komzimba okungaba ngu-15% uyathenjwa, kodwa isifundo sasifushane futhi sincane kunezivivinyo eziyinhloko ze-tirzepatide.

Kubalulekile ukuthi uqaphele ukuthi i-survodutide isesikhathini sezivivinyo zesigaba sesithathu. Izifundo ezinkulu neziqhubekayo zingabonisa izinombolo ezihlukile. Kodwa ngokusekelwe kulokho esinakho namuhla, i-tirzepatide ibonakala ibanga ukuncipha komzimba okukhulu ngokujwayelekile.

Kuthiwani Ngokulawula Ushukela Egazini?

I-Tirzepatide inedatha eqinile lapha. Izivivinyo zezokwelapha zibonise ukuthi yehlise i-HbA1c (ilinganiso likashukela ojwayelekile egazini esikhathini sezinyanga ezintathu) ngamaphesenti angu-2.4 kubantu abane-type 2 diabetes. Lokho kungenye yezingozi ezinkulu ezibonwa nganoma yimaphi amaphilisi ashukela omjovo.

I-Survodutide nayo ibonise ukuthuthuka okuxhomeke kusayizi womthamo emazingeni kashukela egazini esifundweni sayo sezidakamizwa ezinezifo zesifo sikashukela esigabeni sesibili. Noma kunjalo, idatha esethulwayo incane kakhulu futhi imiphumela isaqinisekiswa ezifundweni ezinkulu.

Kubantu abane-type 2 diabetes abafuna inketho evunyiwe njengamanje, i-tirzepatide inesisekelo esiqinile sobufakazi.

I-Survodutide Inenzuzo Kuphi?

Inzuzo eyingqayizivele ye-survodutide yimidlalo yayo ye-glucagon receptor, engayinikeza izinzuzo i-tirzepatide engazinikezi zona.

Impilo yesibindi. Esifundweni sesigaba sesibili sabantu abane-MASH eqinisekiswe yi-biopsy kanye ne-fibrosis yesibindi, u-43% kuya ku-62% weziguli ezithola i-survodutide zafinyelela umgomo oyinhloko wesibindi ngemuva kwamasonto angu-48, uma kuqhathaniswa no-14% nge-placebo. Ukuphakathi kuka-34% no-36% babonise okungenani isigaba esisodwa sokuthuthuka kwe-fibrosis. Le miphumela idale intshisekelo enkulu ngoba i-MASH njengamanje inezindlela zokwelapha ezisebenzayo ezimbalwa kakhulu.

Ukusetshenziswa kwamandla. Umzila we-glucagon ungandisa izinga le-metabolic lokuphumula, okusho ukuthi umzimba wakho ushisa amakhalori engeziwe noma uphumule. Lena yindlela ehlukile kwi-tirzepatide, esebenza ikakhulukazi ngokunciphisa inani odla ngalo.

I-Survodutide ithole izinkomba ze-FDA Breakthrough Therapy kanye ne-Fast Track, ezibonisa ukuthi abalawuli bayibona njengokwelashwa okubalulekile kwezimo ezimbi. Izivivinyo eziningana zesigaba sesithathu kokubili kwezokuphathwa komzimba kanye ne-MASH zisenzeka.

Iziphumo Ezingezinhle Ziyawafanisana Kanjani?

Zombili le mithi zidala imiphumela engemihle kwingqamuzana yokugaya ukudla. Lokhu kuvamile kulo lonke uhla lwemithi esuselwe ku-GLP-1.

Nge-tirzepatide, izimpawu ezingezinhle ezivame ukubikwa zihlanganisa isicanucanu, isifo sohudo, ukuhlanza, nokubanjwa kwesisu. Ezivivinyweni zezokwelapha, cishe u-4.3% kuye ku-7.1% wabahlanganisiwe bayeka ukwelashwa ngenxa yezimpawu ezingezinhle. Izimpawu eziningi ze-GI zazilula kuya kubukhulu obumaphakathi futhi zivame ukuthuthuka ngokuhamba kwesikhathi, ikakhulukazi ngokukhula okancane kwezilinganiso.

Nge-survodutide, uhlu lweziphumo ezingezinhle luyefana: isicanucanu, isifo sohudo, ukuhlanza, nokubanjwa kwesisu. Noma kunjalo, esivivinyweni esisodwa sesigaba sesibili sezidakamizwa ezinezifo zesifo sikashukela, izimpawu ze-GI zabikwa u-55% wabahlanganisiwe be-survodutide uma kuqhathaniswa no-22% nge-placebo. Izilinganiso zokuyeka ngenxa yezimpawu ezingezinhle zibukeka ziphakeme kancane kuneze-tirzepatide, noma kunjalo idatha yokuqhathanisa ngqo akukakafikanga.

Zombili le mithi zidinga ukugcwaliswa okuncane kwezilinganiso (ukuqala phansi nokukhuphuka kancane) ukuze kusizwe umzimba wakho ukuthi uzijwayeze futhi unciphise izimpawu ze-GI.

Iyiphi Ekhona Njengamanje?

I-Tirzepatide inesivumelwane se-FDA futhi iyatholakala ngokuhlinzekwa kukadokotela. Iza ngamapeni omjovo agcwalisiwe ahlinzekwa ngesonto ngo-2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, kanye no-15 mg. Umshwalense ungakukhetha ngaphansi kwezimo ezithile zohlobo lwezifo zesifo sikashukela sohlobo 2 noma ukuphathwa kwesisindo.

I-Survodutide ayivunyelwe noma ayitholakali ngaphandle kwezivivinyo zezokwelapha. Akukho sikhathi esibekiwe sokuvunyelwa, njengoba izivivinyo zesigaba sesithathu zisenzeka. Awukwazi ukuthola ngemithi kadokotela noma ekhemisi ngaleso sikhathi.

Isiphetho

I-Tirzepatide iyinketho evunyiwe, etholakalayo enedatha eqinile yokuncipha komzimba kanye nokulawula ushukela egazini. I-Survodutide iyidakamizwa ejabulisayo esaziswa ngayo engaba nezinzuzo ezihlukile zesibindi kanye ne-metabolic ngokusebenzisa i-glucagon yayo. Uma udinga ukwelashwa manje, i-tirzepatide yiyona ekhethwayo ecacile. Uma imiphumela yesigaba sesithathu ye-survodutide iqinisekisa ithemba layo lokuqala, ingaba inketho ebalulekile esikhathini esizayo, ikakhulukazi kubantu abanesifo samafutha esibindini.